natgillin/translations-raw huggingface dataset:
The method of claim 10, wherein said CD19xCD3 bispecific single chain antibody construct comprises an amino acid sequence as set forth in SEQ ID NO. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što navedeno CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt ima aminokiselinski slijed kako što je iznijet u SEQ ID NO.
EP329348; European Patent Application No. 
Datum objave europske prijave patenta:
The processes of claim 1, wherein said anode grade green coke has the following properties: nickel less than about 175 ppm; vanadium less than about 250 ppm; sulfur less than about 35,000 ppmw; Hardgrove Grindability Index of less than about 100 and Volatile Combustible Matter of less than about 12 wt %. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da navedeni anodni zeleni koks ima sljedeća svojstva: sadržaj nikla manje od oko 175 ppm; vanadija manje od oko 250 ppm; sumpora manje od oko 35,000 ppmw; Hardgrove Indeks mljevenja manje od oko 100 i lako isparljivo gorivo manje od oko 12 % težinskih udjela.
the human Vk1-39/J sequence is operably linked to a mouse Ck region sequence; 
(a) humana sekvenca Vk1-39/JK je operativno povezana sa sekvencom mišje regije Cx;
VLP for use according to claim 1 or 2, whereas the VLP crosses the blood-brain barrier to enter the CNS together with the drug encapsulated by the VLP. 
VLP za uporabu u skladu s patentnim zahtjevom 1 ili 2, dok VLP prelazi krvno-moždanu barijeru za ulazak u CNS zajedno s lijekom koji je enkapsuliran VILP-om.
iv) According to one variant of the invention, the compounds of formula I as defined in embodiment i), ii) or iii) above, or their pharmaceutically acceptable salts, will be such that R3 represents aryl-(C1-C4)alkyl. 
Uporaba prema jednom od zahtjeva 1 do 3, naznačena time, da je spoj formule Ia ili njegova farmaceutski prihvatljiva sol takav/takva da R> predstavlja aril-(C,-C.)alkil.
Most preferably, a compound of formula 1 according to this invention is selected from the group consisting of: 
Spoj formule (IT) prema patentnom zahtjevu 1 odabran iz skupine koju čine: HR P20180973 T1
An antibody polypeptide according to any one of the preceding claims wherein the antibody polypeptide is linked, directly or indirectly, to a therapeutic moiety. 
Polipeptid antitijela prema bilo kojim prethodnim zahtjevima, pri čemu je polipeptid antitijela povezan, direktno ili indirektno, sa terapijskim dijelom.
Compound for use according to claim 9 wherein the disease or condition is diarrhea, lipoprotein disorders, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, migraine, arthritis, hypertension, arrhythmia, ulcer, glaucoma, learning, memory and attention deficits, cognition disorders, neurodegenerative diseases, demyelinating diseases, addiction to drugs and chemical substances including cocaine, amphetamine, ethanol and nicotine; tardive diskinesia, ischemic stroke, epilepsy, stroke, stress, cancer, psychotic conditions, in particular depression, anxiety or schizophrenia; inflammation or autoimmune diseases. 
Spoj namijenjen upotrebi prema zahtjevu 9, naznačen time, da su bolest ili stanje proljev, poremećaji lipoproteina, hiperlipidemija, hipertrigliceridemija, hiperkolesterolemija, pretilost, migrena, artritis, hipertenzija, aritmija, ulkus, glaukom, poremećaji u učenju, pamćenju i pažnji, kognitivni poremećaji, neurodegenerativne bolesti, demijelinizirajuće bolesti, ovisnosti o lijekovima 1 kemijskim tvarima uključujući kokain, amfetamin, etanol i nikotin; tardivna disinzija, ishemijski moždani udar, epilepsija, moždani udar, stres, rak, psihotična stanja, osobito depresija, anksioznost ili shizofrenija; upala ili autoimunih bolesti.
a user data packet sending unit (1340), configured to send user data packets delivered by the SGW to the UE, when the sending end determining unit (1330) determines an end of sending user data packets by the source eNB. 
(1230) dodatno konfigurirana da ne prosljeđuje poseban paket podataka prema UE, kada jedinica koja šalje paket korisničkih podataka (1230) šalje pakete korisničkih podataka isporučene od SGW prema UE.
The apparatus as claimed in claim 1, further comprising a first magazine for accommodating one, two or more replacement reservoir units for the first reservoir unit (8). 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno sadrži prvi spremnik za smještaj jedne, dvije ili više zamjenskih jedinica spremnika za prvu jedinicu spremnika (8).
The primary aim of this test was the evaluation of liver function, by measuring the clearance of a single, i.v. 
Osnovni cilj ovog ispitivanja bio je procjena jetrenih funkcija, mjerenjem klirensa jedne i.v.
The compound of claim 8, wherein X is 4-pyridinyl optionally substituted with one substituent selected from the group consisting of C1-C4 alkyl, cyclopropyl, cyclopropyloxy, cyclopropylmethyl, C1-C4 alkoxy, CF3, amino, alkylamino, dialkylamino, thioalkyl, halogen, alkylsulfonyl and cyano. 
Spoj prema zahtjevu 8, naznačen time da je X 4-piridinil opcionalno supstituiran jednim supstituentom izabranim iz skupine koju sačinjavaju C;-C4 alkil, ciklopropil, ciklopropiloksi, ciklopropilmetil, C,-Ca alkoksi, CF3, amino, alkilamino, dialkilamino, tioalkil, halogen, alkilsulfonil i cijano.
A bulky precipitate is formed in both cases. 
Formira se pozamašan talog u oba slučaja.
The composition of claim 1 or 2, wherein the metal halide salt is selected from the group consisting of sodium chloride and potassium chloride. 
Pripravak 17 patentnog zahtjeva 1 ili 2, naznačeno time da je sol metalnog halogenida odabrana iz skupine koju čine natrijev klorid 1 kalijev klorid.
The mixture is heated under reflux for 1 h, cis-1,4-dichlorobut-2-ene (27 g, 0.216 mole) in THF (100 mL) is added dropwise to the reaction mixture at 75°C over a period of 15 min. The reaction mixture is heated under reflux for 5 h, cooled to room temperature and quenched with water (50 mL). 
Smjesu se grije 1 sat na refluksu, zatim se cis-1,4-diklorbut-2-en (27 g, 0,216 mol) u THF-u (100 ml) 15 minuta ukapava u reakcijsku smjesu na 75 *C. Reakcijsku smjesu se grije 5 sati na refluksu, ohladi do sobne temperature, te ugasi vodom (50 ml).
MI is a transition metal of group IB, or group 11 in the IUPAC nomenclature, 
M je prijelazni metal iz skupine Ig, ili skupine 11 u IUPAC-ovoj nomenklaturi,
The lock (10) further includes a slide (17), which slides with respect to the body (11); the stop element (14) is slidably constrained to a guide element. 
- - kliznik (17), koji klizi u odnosu na navedeno tijelo (11), gdje je navedeni zaustavni element (14) klizno ograničen na navodeći element; -
shows the cumulated viable cells; 
prikazuje ukupne vijabilne stanice;
a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and 
mutirani ptr gen, pri čemu mutirani ptr gen kodira Proteaza III protein koji ima smanjenu proteaznu aktivnost ili je nokaut mutirani ptr gen; i
Imazamox, including its respective isomers a s well as its respective environmentally compatible salts or esters or amides or other derivatives; and 
B) metazaklor i kvinmerak uključujući njihove odgovarajuće izomere, kao i njihove odgovarajuće soli, estere, amide ili druge derivate kompatibilne sa životnom sredinom.
wherein: is selected from the group consisting of 
je odabran iz skupine koju čine i R5;
The warm mixture was stirred for 1 hour, then kept cool on a water bath at room temperature (20°) while a solution.of ethyl 4-chloroacetoacetate (16.5 g) in dry THF (100 ml) was added dropwise over 3.5 hours. 
Topla smjesa se miješa 1 sat, tada se održava hladnom na vodenoj kupelji na sobnoj temperaturi (20%) dok se ukapavanjem tijekom 3,5 sata dodaje otopina etil 4-kloroacetata (16,5 g) u suhom THF (100 ml).
The soil working tool according to claim 1, wherein one or more hard-material coverings are arranged in a region of the front side of the carrier. The soil working tool according to claim 10, wherein the hard-material coverings are inserted into recesses of the carrier. 
Uređaj za obradu zemlje prema jednom od zahtjeva 1 do 7, naznačen time da su u području prednje strane nosača (10) poredane jedna ili više navlaka od čvrstog materijala (30).
This has disadvantages in that after the use of a substantial number of capsules a wearing off of the fixed sealing means can take place such that the quality of the produced beverage is increasingly deteriorated by water passing the no longer properly efficient sealing. SUMMARY OF THE INVENTION 
Ovo rješenje ima takav nedostatak, da nakon upotrebe znatnog broja čahura može nastupiti trošenje fiksiranog sredstva za brtvljenje, tako da se kvaliteta pripremljenog napitka sve više pogoršava zbog prolaza vode kroz brtvu koja više ne brtvi kako bi trebalo.
The compound of formula (I') of anyone of claims 5 to 8 for its use according to claim 9, wherein the diabetes is type 2 diabetes mellitus. 
Spoj formule (I) iz bilo kojeg od patentnih zahtjeva 5 do 8 za njegovu primjenu prema patentnom zahtjevu 9, gdje je dijabetes tip 2 dijabetes melitusa.
An indolizine derivative as claimed in claim 3, wherein R2a and R2b independently represent any of the following (b1) to (b4): 
Derivat indolizina prema zahtjevu 3 ili 4, gdje R* i R* nezavisno predstavljaju bilo što od sljedećeg (b1) do (b4):
A further embodiment of the present invention relates to compounds of the formula (Ia″), where the compounds of the formula (Ia″) are compounds of the formula (I-T23) 
7. Spojevi prema zahtjevu 1, naznačeni time da spojevi s formulom (1a") su spojevi s formulom (I-T46)
Smoking article The present invention relates to a smoking article which produces an aerosol that resembles tobacco smoke, and which contains no more than a minimal amount of incomplete combustion or pyrolysis products. 
(57) Sažetak: = Pronalazak se odnosi na proizvod za pušenje koji proizvodi aerosol koji je sličan duhanskom dimu, ali sadrži samo minimalnu količinu proizvoda nekompletnog sagorijevanja ili pirolize.
The control means and valve means of the beverage production device can be configured to, upon user's input, selectively activate two thermoblocks out of the three thermoblocks such that hot water is selectively supplied at least to: 
Sustav za kontrolu i ventile naprave za proizvodnju napitaka može se podesiti da, kada to korisnik zatraži preko kontrolne ploče, selektivno aktivira dva od tri termobloka, tako da se vruću vodu selektivno dovodi u najmanju ruku u:
The device (11) according to claim 15, wherein said cavity inlet (210) is defined by a frustoconical surface. 
Uređaj (11) u skladu s patentnim zahtjevom 15, naznačen time, da navedeni ulaz šupljine (210) ima površinu u obliku krnjeg stošca.
The system of claim 9 wherein the first electrical source is implanted; and wherein the controller component is operatively connected to the first electrical source by a wireless connection. 
Sustav sukladno zahtjevu 1 pri čemu je prvi električni izvor također usađen; i pri čemu je kontrolna komponenta operativno povezana s prvim električnim izvorom pomoću bežične veze.
The capsularhexis device of claim 1, wherein the superelastic wire is formed from a nickel titanium alloy. 
Instrument za kapsuloreksu prema zahijevu 1, naznačen time, da je superelastična žica načinjena od legure nikla i titanija.
The composition of claim 3, wherein the composition is for use in a method of treating or preventing rheumatoid arthritis, and wherein the composition is for use in a method of reducing joint swelling in rheumatoid arthritis. 
Pripravak prema zahtjevu 2, naznačen time da je pripravak za upotrebu u postupku liječenja ili prevencije reumatoidnog artritisa, i pri čemu je pripravak za upotrebu u postupku smanjenja naticanja zglobova kao reumatoidnog artritisa.
The reaction is placed under hydrogen on a Parr shaker at 25 psig at room temperature. 
Reakcijsku smjesu stavi se u atmosferu vodika na Parrovoj tresilici na 273,7 kPa (25 psig) na sobnoj temperaturi.
The jacketed tube of claim 14 further comprising at least one metal tube containing a fiber optic cable, electrical wire or data communication cable (20), (21). 
Obložena cijev u skladu s patentnim zahtjevom 14, naznačena time što dodatno sadrži najmanje jednu metalnu cijev, koja sadrži kabel od staklenog vlakna, električnu žica ili komunikacijski kabel (20), (21).
The chemically modified glycosaminoglycan according to any one of claims 1-2, comprising non-reducing end unsaturated glucosamines presented as signals in the interval of 5.0 to 6.5 ppm in a 1H-NMR spectrum with an intensity (% ratio) of less than 4% in relation to the signal at 5.42 ppm from native heparin. 
3. < Kemijski modificirani glikozaminoglikan prema bilo kojem od zahtjeva 1-2, naznačen time da sadrži nereducirajući kraj nezasićenih glukozamina koji su predstavljeni kao signali u intervalu 5,0 do 6,5 ppm u IH- NMR spektru s intenzitetom (% omjera) manjim od 4% u odnosu na signal na 5,42 ppm od izvornog heparina.
The system according to claim 1, wherein the user receiver is provided with a digital signal processor, arranged to distinguish particular emergency service signals from interference signals. 
Sustav prema zahtjevu 7, pri čemu je spomenuti korisnički prijemnik (R) opremljen drugim pojasnim propusnim filtrom (6) za ponovno filtriranje signala koje je obradio sklop za miješanje.
obtaining a slice-level initial QP for predicting the QP used to perform inverse quantization on the coding units included in the slice segment, based on the obtained syntax; 
pribavljanje (2820) početnog QP na razini odsječka za predviđanje QP koji se koristi za provođenje inverzne kvantizacije na jedinicama za kodiranje uključenim u odsječak, na temelju dobivenog elementa sintakse;
The ethyl acetate layer was evaporated and purified by preparative LC/MS to give 11-1 (5 mg, 12% yield). 
Etil-acetatni sloj se otpari, te pročisti preparativnim sustavom LC/MS kako bi se dobilo 11-1 (5 mg, prinos od 12 %).
A compound according to claim 4 wherein R1 represents C4-6 alkyl. 
Spoj u skladu s patentnim zahtjevom 4, naznačen time, da R1 predstavlja C4-6 alkil.
The pharmaceutical composition of Claim 23, wherein the: insulin lispro concentration is about 100 IU/mL; treprostinil concentration is from 0.05 to 26 µM; meta-cresol concentration is about 3.15 mg/mL; and the pH of the composition is about 7.4. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 23, naznačen time što: koncentracija inzulina lispro je otprilike 100 IU/ml; koncentracija treprostinila se kreće od 0,05 do 26 µM; koncentracija meta-krezola je otprilike 3,15 mg/ml, a pH pripravka je otprilike 7,4.
Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. 
Općenito, poželjni su nevodeni mediji poput etera, etil-acetata, etanola, izopropanola ili acetonitrila.
At least one humectant is selected from the groups consisting of hexylene glycol, glycerin, propylene glycol, sorbitol, lactic acid, sodium lactate, mannitol, butylene glycol, panthenol, hyaluronic acid, urea, chitosan, polyols, methyl gluceth-10, methyl gluceth-20, and polyethylene glycols. 
(i) grupe koja se sastoji od heksilen glikola, glicerina, propilen glikola, sorbitola, mliječne kiseline, natrijevog laktata, manitola, butilen glikola, pantenola, hijaluronske kiseline, uree, kitozana, poliola, metil glucet-10, metil glucet-20 i polietilen glikola; ili
A stable solid pharmaceutical dosage form for oral administration, after being constituted in water, comprising: 
Čvrsti farmaceutski dozirni oblik, naznačen time, da je za oralnu primjenu, nakon što se dobije u vodi, a sadrži:
The mooring buoy of claim 3, wherein the controller is configured to activate the RF communication device to receive the vessel ID upon detecting via the movement sensor that the buoy is in a mooring position, and the controller is further configured to communicate the vessel ID to the booking system via the cellular antenna. 
Plutača za privez (101) prema zahtjevu 3, naznačena time što je kontroler postavljen da aktivira RF komunikacijski uređaj radi prijema ID plovila nakon otkrivanja putem senzora kretanja da je plutača u položaju za privez, a kontroler je nadalje postavljen da putem mobilne antene komunicira ID plovila prema sustavu za rezervaciju.
The method of item 30, wherein the condition is an eye disorder. 
Farmaceutski pripravak za uporabu prema zahtjevu 30, naznačen time da je stanje poremećaj oka.
The method of Claim 1 or Claim 2, wherein said parent bacterial strain is selected from Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Agrobacterium, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Rickettsia, Shewanella, Serratia, Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, and Oenococcus. 
Postupak prema zahtjevu 1, naznačen time da je navedeni matični bakterijski soj odabran od bakterija Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, = Listeria, - Agrobacterium, = Staphylococcus, = Streptococcus, = Enterococcus, = Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Ricketisia, Shewanella, Serratia, Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, te Oenococcus.
The process of claim 20, wherein the catalyst concentration is sufficiently low to retrieve an ultra high molecular weight polyethylene having an intrinsic viscosity of at least 7.5 dL/g measured according to ASTM D2857. 
Postupak prema patentnom zahtjevu 7, naznačen time da je koncentracija katalizatora manja od 0,05 mM kako bi se dobio polietilen ultra visoke molekulske mase čija unutrašnja viskoznost iznosi najmanje 7,5 dUg, izmjereno prema ASTM D2857.
at least one feeding line of water to at least one containing means; 
najmanje jednu liniju napajanja (7) vode u najmanje jedno sredstvo za spremanje (8);
a pilot inserter (404) configured to insert pilot signals into the signal frame; a modulator (104) configured to modulate the signal frame, into which the pilot signals are inserted, by an Orthogonal Frequency Division Multiplexing,OFDM, method; and 
modulator (104) konfiguriran za moduliranje izgrađenog okvira signala pomoću metode ortogonalnog umnožavanja dijeljenja frekvencije, OFDM; i jedinicu za prijenos konfiguriranu za prijenos moduliranog okvira signala.
Reduction with Lithium Aluminum Hydride [3H]—This procedure offers products at almost theoretical specific activities. 
C. Redukcijom sa litij aluminij hidridom [PH] - Taj postupak nudi produkte gotovo teoretske specifične aktivnosti.
The communication apparatus of claim 1, further adapted to synchronize the time of the communication apparatus to universal time and to communicate the synchronized time to each of the plurality of EDRs. 
Komunikacijski uređaj sukladno zahtjevu 1, naznačen time, da je nadalje prilagođen sinhronizirati vrijeme komunikacijskog uređaja s univerzalnim vremenom i prenositi sinhronizirano vrijeme svakom od mnoštva EDR-a.
This occurs in favor of the process economy both in terms of lower investment (smaller stands) and of less power required for the same thickness of the end product. 
To ide u prilog ekonomičnosti postupka, i u pogledu nižih ulaganja (manji stanovi) i u tom pogledu što je za jednaku debljinu završnog proizvoda potrebno manje energije.
A process for preparing a compound of the formula I 
Postupak dobivanja spoja formule I gdje
Recombinant expression may be carried out in prokaryotic expression systems like E. coli, or in eukaryotic, and preferably in mammalian, expression systems. 
Rekombinantna ekspresija može se provoditi u prokariotskim sustavima poput E. coli ili u eukariotskim, a najpoželjnije su stanice sisavaca.
Transfer an amount of material equivalent to 100 mg solids into a 100 mL volumetric flask, dilute to volume with water, mix and centrifuge if the solution is cloudy. 
Prenese se količina materijala ekvivalentna 100 mg čvrste tvari u 100 mL volumetrijsku tikvicu, razrijedi do volumena s vodom, pomiješa i centrifugira ako je otopina zamućena.
applying said sample to the solid support under conditions wherein said target DNA, proteins and other cellular components are present at the same proportion as in said in vivo source, whereby the target DNA is fragmented by the transposome complexes, and the 3′ transposon end sequence of the first polynucleotide is transferred to a 5′ end of at least one strand of the fragments; thereby producing an immobilized library of double-stranded fragments wherein at least one strand is 5′-tagged with the first tag. 
(b) stavljanju ciljane dvolančane DNA na čvrsti nosač u uvjetima u kojima se ciljanu DNA fragmentira transposomskim kompleksima, a terminalni slijed transposona na 3* kraju prvog polinukleotida se prebacuje na 5* kraj najmanje jednog lanca fragmenata; čime se dobiva imobiliziranu biblioteku dvolančanih fragmenata gdje je najmanje jedan lanac 5'-obilježeni prvim biljegom iz prvog slijeda, a najmanje jedan lanac je 5/- obilježeni prvim biljegom iz drugog slijeda.
A method according to Claim 1 comprising steps (a) and (b), wherein steps (a) and (b) are carried out at different time points from the addition of a carbon source to the culture medium. 
Postupak prema patentnom zahtjevu 2, naznačen time što postupak sadrži barem korak (a) i korak (b), i pri čemu se korak (a) i korak (b) provode u različitim vremenskim točkama od dodavanja izvora ugljika medija za kultiviranje.
A nucleic acid molecule that encodes the antibody of any of claims 1-4 or the specific binding agent of claim 8. 
Molekula nukleinske kiseline koja kodira antitijelo ili antigen vezujući fragment istog prema jednom od zahtjeva 1 do 13.
A process for the conversion of a feedstock containing one or more triglycerides of fatty acids to a mixture containing one or more alkyl esters of fatty acids and t-alkyl glycerols, comprising the reaction of said feedstock with a compound of formula (I): 
PATENTNI ZAHTJEVI 1. > Postupak za pretvorbu sirovine koja sadrži jedan ili više triglicerida masnih kiselina u smjesu koja sadrži jedan ili više alkil-estera masnih kiselina i t-alkilglicerola, koji obuhvaća reakciju rečene sirovine sa spojem formule (I):
The process of claim 1, wherein the oxycodone hydrochloride composition has a 14-hydroxycodeinone level of less than 15 ppm. 
Postupak prema zahtjevu 1, naznačen time da rezultantni sastav oksikodon hidroklorida sadrži 14-hidroksikodeinon u količini manjoj od 15 ppm.
In various embodiments the benzoic acid, benzoic acid salt, benzoic acid ester, and/or benzoic acid derivative is a benzoic acid salt. In various embodiments the benzoic acid, benzoic acid salt, benzoic acid ester, and/or benzoic acid derivative is selected from the group consisting of benzoic acid, sodium benzoate, potassium benzoate, calcium benzoate, 2-aminobenzoate, 3-aminobenzoate, and 4-aminobenzoate. 
Benzojeva kiselina ili sol benzojeve kiseline za uporabu u metodi ublažavanja jednog ili više simptoma shizofrenije pri čemu se sol benzojeve kiseline bira iz skupine koja se sastoji od natrijevog benzoata, kalijevog benzoata, kalcijevog benzoata i litijevog benzoata i pri čemu je količina benzojeve kiseline ili soli benzojeve kiseline dovoljna za ublažavanje jednog ili više spomenutih simptoma i varira od približno 5 mg do približno 500g.
With reference to Figures 1 and 2, a first embodiment of a breathable and waterproof shoe according to the invention is generally designated by the reference numeral 10. 
U vezi sa Slikama 1 1 2, prvo utjelovljenje prozračne i vodootporne cipele sukladno predmetnom izumu općenito se označava brojčanom referencom 10.